A tad ugly, however well supported by shareholders, Directors and new players. I am sure this will be followed up with news flow from the new marketing appointments, FDA and possible realigning of senior staff that is well overdue.
A tad ugly, however well supported by shareholders, Directors...
Add to My Watchlist
What is My Watchlist?